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CD  Circular dichroism 
CLSM   confocal laser scanning microscopy 
ELISA   Enzyme-linked immunosorbent assay  
L-leu  L-leucine 
NGI  Next generation impactor 
NPs  Nanoparticles 
NCMPs Nanocomposite microparticles 
PGA-co-PDL Poly(glycerol adipate-co-ω-pentadecalactone) 
PspA4Pro pneumococcal surface protein A 
PVA  Polyvinyl alcohol 
SD  Spray-drying 
SDS-PAGE  Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
Pneumonia, caused by Streptococcus pneumoniae, mainly affects the immune 
compromised, the very young and the old, and remains one of the leading causes of death. 
A steady rise in disease numbers from non-vaccine serotypes necessitates a new vaccine 
formulation that ideally has better antigen stability and integrity, does not require cold-chain 
and can be delivered non-invasively. In this study, a dry powder vaccine containing an 
important antigen of S. pneumoniae, pneumococcal surface protein A (PspA) that has shown 
cross-reactivity amongst serotypes to be delivered via the pulmonary route has been 
formulated. The formulation contains the antigen PspA adsorbed onto the surface of 
polymeric nanoparticles encapsulated in L-leucine microparticles that can be loaded into 
capsules and delivered via an inhaler. We have successfully synthesized particles of ~150 
nm and achieved ~ 20 µg of PspA adsorption per mg of NPs. In addition, the spray-dried 
powders displayed a FPF of 74.31±1.32% and MMAD of 1.70±0.03 μm suggesting a 
broncho-alveolar lung deposition facilitating the uptake of the nanoparticles by dendritic 
cells. Also, the PspA released from the dry powders maintained antigen stability (SDS-
PAGE), integrity (Circular dichroism) and activity (lactoferrin binding assay). Moreover, the 
released antigen also maintained its antigenicity as determined by ELISA. 
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1. Introduction 
Pneumococcal diseases are infections caused by Streptococcus pneumoniae, also known 
as pneumococcus, which utilizes the respiratory tract as a portal of entry into the body. 
Pneumococcal diseases are classified into non-invasive pneumococcal diseases (otitis 
media, sinusitis, non-bacteremic pneumonia) or invasive pneumococcal diseases (IPD) 
(septicemia, meningitis, pneumonia) (Jambo et al., 2010). S. pneumoniae is the leading 
cause of bacterial pneumonia worldwide amongst the immuno compromised, the elderly, 
children under the age of 5, and adults in the developed world which is likely to increase with 
an aging population (Wardlaw et al., 2006). 
Currently, two pneumococcal vaccine types are available, polysaccharide vaccine (23-
valent) and conjugate vaccine (10 or 13-valent) (Bogaert et al., 2004; Wang and Curtiss III, 
2014). The conjugate vaccines have shown higher efficacy for invasive infections compared 
to polysaccharide vaccines; but have lower levels of protection against mucosal diseases, 
such as pneumonia. Furthermore, these vaccines do not protect against non-vaccine 
serotypes, which has led to the emergence of diseases caused by these serotypes (Hicks et 
al., 2007; Singleton et al., 2007). Moreover, conjugate vaccines are expensive, complicated 
and time consuming to manufacture thus limiting their usage especially in the low and middle 
income countries (LMICs) where a significant burden of the disease is reported (Walker et 
al., 2013). Consequently, with more than 90 serotypes identified and a steady rise in 
diseases by non-vaccine serotypes being reported, further emphasis on identifying and 
developing alternate vaccine candidates to be employed in an effective vaccine delivery 
system has gained importance (Miyaji et al., 2013).  
Pneumococcal infections are mostly preceded by colonization of the upper airways and 
nasal carriage is a primary source of infection in humans (Kadioglu et al., 2008). Therefore, 
an optimal vaccination strategy would be to deliver the antigen via a mucosal route providing 
protection against both the colonizing bacteria and invasive disease. In addition, the 
activation of the immune system requires the effective delivery of antigen to APCs such as 
dendritic cells (DCs) which process the internalized antigen thereby generating an immune 
response (Kwon et al., 2005). 
Institutes such as US NIH and PATH have elaborated on the usage of pneumococcal 
proteins as alternate vaccine candidates for their ubiquitous presence across serotypes 
(Ginsburg et al., 2012). These proteins have the ability to protect against all serotypes thus 
preventing the prevalence of serotypes (Ginsburg et al., 2012; Wang and Curtiss III, 2014). 
Among the different types of pneumococcal proteins such as pneumococcal surface protein 
A (PspA), pneumococcal surface protein C (PspC), pneumolysin; PspA is one of the most 
promising candidates and has been widely investigated by several groups (Briles et al., 
2000a; Briles et al., 2000b; Haughney et al., 2013; Moreno et al., 2010; Ogunniyi et al., 
2007; Ogunniyi et al., 2001; Vadesilho et al., 2012). The main function of PspA is preventing 
the deposition of complement on the surface of the bacterium thereby inhibiting opsonization 
and phagocytosis (Ren et al., 2004a; Ren et al., 2004b). PspA was also shown to inhibit 
death by apolactoferrin at mucosal sites (Shaper et al., 2004). 
Vaccination with PspA has shown to induce protective antibodies in humans (Briles et al., 
2000b; Nabors et al., 2000). However, recombinant protein based vaccines can be poorly 
immunogenic generating low antibody responses in the absence of adjuvants or delivery 
systems. Research is now focused on delivering antigens via particulate carriers where the 
antigen can be associated with the particles acting as delivery systems with the added 
benefit of augmenting the generated immune response upon uptake by antigen presenting 
cells (APCs) (O'Hagan, 2001). In addition, particulate antigens are known to generate a 
stronger immune response compared to soluble antigen (Koppolu and Zaharoff, 2013). As 
such, research has been focused on using polymeric nanoparticles (NPs) as delivery 
vehicles for antigen delivery (Kong et al., 2013; Koppolu and Zaharoff, 2013). Lately, it has 
also been shown by different groups that polymeric particles have enhanced the 
immunogenicity of PspA (Anish et al., 2014; Haughney et al., 2013; Kong et al., 2013).  
A dry powder vaccine delivered via the inhalation route can overcome certain challenges 
such as invasiveness, cold-chain requirements, low stability and integrity of the antigen that 
are often associated with the traditional liquid based vaccines currently available in the 
market (Al-fagih et al., 2011; Blank et al., 2011; Kunda et al., 2013). To address these issues 
in this study, a dry powder vaccine containing antigen adsorbed polymeric NPs for delivery 
via inhalation was successfully developed. In addition, NPs uptake by DCs was visualized. 
Due to their low inertia, NPs are likely to be exhaled upon inhalation and thus have been 
encompassed in microparticles by spray-drying using L-leucine (L-leu) as a microcarrier 
(Kunda et al., 2015). Furthermore, the effect of the formulation process on the stability, 
integrity, antibody recognition and activity of PspA was investigated. 
 
2. Materials and Methods  
 
2.1. Materials 
Acetonitrile (HPLC grade), glycerol, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), human lactoferrin, nile red dye (NR), phosphate buffered saline (PBS) 
tablets, poly(vinyl alcohol) (PVA, MW 9-10 KDa, 80%), trifluoroacetic acid (TFA, HPLC 
grade), Tween 80® and antibiotic/antimycotic (100X) solution were obtained from Sigma-
Aldrich, UK. L-leucine (L-leu) was purchased from BioUltra, Sigma, UK. Tissue culture flasks 
(25 and 75 cm2) with vented cap, 96-well flat bottom and U shaped plates, acetone, dimethyl 
sulfoxide (DMSO) and tetrahydrofuran were purchased from Fisher Scientific, UK. Alpha 
minimum essential medium (α-MEM) and granulocyte macrophage colony-stimulating factor 
(GM-CSF) was purchased from Life technologies, UK. Fetal calf serum (FCS) heat 
inactivated was purchased from Biosera UK. Micro BCA™ protein assay kit was purchased 
from Thermo Scientific, UK. Dendritic cell lines, JAWS II (CRL-11904™) were purchased 
from American type culture collection (ATCC). The biodegradable polymer, poly(glycerol 
adipate-co-ω-pentadecalactone), PGA-co-PDL was synthesized as described previously 
(Thompson et al., 2006). 
 
2.2. Preparation of Nanoparticles and Characterization 
The polymeric NPs were prepared using the synthesized polymer as previously 
described (Kunda et al., 2015). Briefly, 200 mg of PGA-co-PDL was dissolved in 2 ml DCM 
and probe sonicated (20 μm amplitude) for 2 min under ice and upon addition to 5 ml of 10% 
w/v PVA formed an emulsion. This was then added drop wise to 20 ml of 0.75% w/v PVA 
under magnetic stirring at a speed of 500 RPM. The mixture was left stirring for 3 h at room 
temperature to facilitate the evaporation of DCM. Nile Red, (NR) 0.5 mg was added to the 
organic phase to prepare dye loaded NPs for characterization by confocal microscopy. 
Particle size, poly dispersity index (PDI) and zeta-potential were measured by laser 
diffraction using a laser particle size analyzer (Zetasizer Nano ZS, Malvern Instruments Ltd, 
UK). For NP suspensions, an aliquot of 100 μl was diluted with 5 ml of deionized water and 
for NP suspensions with protein adsorption, 2 mg of NPs were resuspended in 5 mL of 
deionized water, loaded into a cuvette and the measurements were recorded at 25°C (n=3). 
 
2.3. Production and Purification of PspA4Pro 
 The N-terminal α-helix and the first block of the proline rich region of PspA from clade 4 
(PspA4Pro), fragment with cross reactivity with PspA from other clades (Moreno et al., 
2010), was cloned into pET37b+ and expressed in E. coli BL21 (DE3). The protein was 
produced and purified using previously published methods with slight modifications 
(Carvalho et al., 2012; Horta et al., 2012; Horta et al., 2014). The production of recombinant 
PspA4Pro was performed in 5 L bioreactors using; fed-batch cultivation with defined medium 
containing glycerol as carbon source and lactose as inducer (Horta et al., 2012) or batch 
cultivation with complex medium containing glucose, glycerol and lactose for auto-induction 
(Horta et al., 2014). The purification method consisted of cell disruption in a continuous high 
pressure homogenizer, precipitation of the homogenate with cetyltrimethylammonium 
bromide, pellet removal by centrifugation, anion exchange chromatography in Q-Sepharose, 
cryoprecipitation and cation exchange chromatography in SP-Sepharose (Carvalho et al., 
2012). The desired PspA4Pro purity (>95%) and the developed process also removed 
lipopolysaccharide, yielding acceptable levels of endotoxin (0.3-0.6 EU/ml) in the final 
product (Brito and Singh, 2011).  
 
2.4. PspA4Pro Adsorption and Quantification 
NP suspensions were collected by centrifugation  (78,000 g, 40 min, 4 °C) and 
resuspended in 4 ml of PspA4Pro at a ratio of 100:20 (NP:PspA4Pro). The mixture 
was left rotating on a HulaMixer™ Sample Mixer (Life Technologies, Invitrogen, UK) 
for 1 h at room temperature and 20 RPM. The PspA4Pro adsorbed NPs were then 
centrifuged, as above and the supernatant analyzed for protein content using a micro 
BCA protein assay kit. The amount of protein adsorbed in µg per mg of NPs (n=3) 
was calculated using Eq. (1): 
 
Adsorption (µg per mg of NPs) = (Initial protein concentration-Supernatant protein concentration)
Amount of NPs
   (1) 
 
The particle size, PDI and zeta-potential of NPs with and without PspA4Pro adsorption were 
measured as above. 
 
2.5. Preparation and Characterization of Nanocomposite Microparticles 
Nanocomposite microparticles (NCMPs) incorporating PspA4Pro adsorbed NPs were 
prepared by spray-drying using a Büchi B-290 mini spray-dryer (Büchi Labortechnik, Flawil, 
Switzerland) with a nozzle atomizer diameter of 0.7 mm and fitted with a high-performance 
cyclone. The NPs were suspended in L-leu solution at a NPs-to-carrier ratio of 1:1.5 w/w and 
spray-dried at a feed rate of 10% with an atomizing air flow of 400 L/h, aspirator capacity of 
100% and an inlet temperature of 100 °C (outlet temperature of 45–47 °C). The dry particles 
were collected and stored in a desiccator at room temperature until further use. The resultant 
NCMPs were characterized as follows: 
Yield: The dry powder yield % (w/w) was determined as the difference in the weight of the 
sample vial before and after product collection compared to the initial total dry mass (n=3). 
Morphology: Spray-dried PspA4Pro adsorbed NPs/NCMPs were mounted on aluminum pin 
stubs (13 mm) layered with a sticky conductive carbon tab and coated with palladium (10–15 
nm) using a sputter coater (EmiTech K 550X Gold Sputter Coater, 25 mA, 3 min), and 
visualized using scanning electron microscopy (FEI Quanta™ 200 ESEM, Holland). 
 
2.6. In vitro Release Studies 
The in vitro release studies were performed by adding 20 mg of PspA4Pro adsorbed 
NPs/NCMPs into eppendorfs and then dispersed in 2 ml of PBS, pH 7.4. The samples were 
incubated at 37 °C and left rotating for 48 h at 20 RPM on a HulaMixer™ Sample Mixer (Life 
Technologies, Invitrogen, UK). At pre-determined time intervals up to 48 h, the samples were 
centrifuged (accuSpin Micro 17, Fisher Scientific, UK) at 17,000 g for 30 min and 1 ml of the 
supernatant removed and replaced with fresh medium. The supernatant was analyzed using 
the HPLC method as mentioned below. Each experiment was repeated in triplicate and the 
result was the mean value of three different samples (n=3). The percentage cumulative 
protein released was calculated using Eq. (2): 
 
% Cumulative protein released = Cumulative protein released
Protein loaded
 × 100     (2) 
 
2.7. High Performance Liquid Chromatography Method 
 A HPLC method was developed to quantify the amount of protein, PspA4Pro, present in 
a given sample. The optimum chromatographic conditions employed were as follows: HPLC 
system Agilent 1100 series (Santa Clara, CA, USA) equipped with a column (Aeris 3.6 μm 
C4 200A Wide Pore 4.6mm i.d. x 150 mm length), security cartridge of the same material 
(Phenomenex, UK) and software for data processing; mobile phase was composed of (A) 
0.1% w/v TFA in water and (B) 0.1% w/v TFA in acetonitrile with a gradient flow of A/B from 
80:20 to 35:65 in 25 min, post-time 6 min; flow rate of 0.8 ml/min; injection volume of 100 μl; 
run temperature 40 °C; UV detection at 214 nm and pspA4Pro retention time of 14.9 min. 
The protein calibration curve was prepared from stock solution (1 mg/ml) in HPLC water and 
PBS (pH 7.4) to obtain the following concentrations: 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 200 
μg/ml of protein (n = 9, R2 = 0.999). 
 
2.8. Investigation of PspA4Pro Structure and activity 
2.8.1. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
The primary structure of PspA4Pro released from the NPs/NCMPs after spray-drying 
was determined by SDS-PAGE. A 9% stacking gel (Geneflow Limited, UK) containing 0.4% 
SDS and protein loading buffer blue (2X) was added to the samples in a 1:1 (v/v) buffer-to-
sample ratio. Samples were loaded (25 μl per well) and the gel was run for 2.5 h at a voltage 
of 100 V with Tris-glycine-SDS PAGE buffer (10X). The gel was stained with colloidal 
coomassie blue and left overnight in distilled water for destaining and imaged using a gel 
scanner (GS-700 Imaging Densitometer, Bio-Rad) equipped with Quantity One software. 
 
2.8.2. Circular Dichroism (CD) 
The secondary structure of the released PspA4Pro was determined by CD 
spectroscopy using a J-815 spectropolarimeter (Jasco, UK) at 20 °C as previously described 
(Kunda et al., 2015). A 10 mm path-length cell was used to perform five scans per sample at 
a scan speed of 50 nm/min over wavelength 260 to 180 nm at a data pitch of 0.5 nm and 
band width of 1 nm. The baseline acquired in the absence of samples was subtracted 
(Henzler Wildman et al., 2003) and the secondary structure of the samples was estimated 
using the CDSSTR method (reference protein dataset 3) from the DichroWeb server 
(Whitmore et al., 2010).  
 
2.8.3. Antibody Recognition Test of PspA4Pro Integrity 
The protein integrity was determined by antibody recognition using Enzyme-linked 
immunosorbent assay (ELISA) as previously described by Haughney et al. with slight 
modifications (Haughney et al., 2013). Briefly, released PspA4Pro (50 µl, 0.5 µg/ml) was 
coated on a high binding 96-well plate (Costar 96-Well Microplates, Cole-Parmer, UK) 
followed by incubation overnight at 4 ºC. The PspA4Pro solution was removed from the wells 
and blocking buffer, PBS with 1% fish gelatin (Sigma Aldrich, UK), was added and incubated 
for 2 h at room temperature. After incubation, the buffer was removed and the wells were 
washed with PBS containing 0.5% Tween 20 (PBS-T) (3x). The anti-PspA monoclonal 
antibody 22003 (QED Bioscience, San Diego, CA) (100 µl, 1 µg/ml) was added to each well 
and incubated overnight at 4 ºC. The plates were then washed with PBS-T (3x) followed by 
addition of alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson 
ImmunoResearch Europe Ltd, UK) (100 µl, 0.1 µg/ml). The plates were incubated for 2 h at 
room temperature and 200 µl of alkaline phosphatase yellow (pNPP) liquid substrate buffer 
(Sigma Aldrich, UK) was added and incubated for 15 min at room temperature to develop 
the ELISA. The colorimetric changes were measured at 405 nm using a microplate reader 
(Epoch, BioTek Instruments Ltd, UK). The ratio of absorbance between the released 
PspA4Pro and the native protein was represented as relative antibody recognition. 
 
2.8.4. Lactoferrin Binding  
5 mg of PspA4Pro adsorbed NPs/NCMPs NP/NCMPs were incubated for 4 h in 500 
µL PBS pH 7.4 at 37 °C with shaking. Samples were centrifuged at 15,700 g for 15 min, from 
which 30 µL of the supernatant was loaded onto a SDS-PAGE gel and samples were 
transferred to a nitrocellulose membrane, which was incubated with biotin-labeled lactoferrin 
(Human lactoferrin labeled with biotin using a Biotin Labeling Kit (Roche Life Sciences)). 
Lactoferrin binding was evaluated by incubation with streptavidin-HRP (BD Biosciences) and 
detection using Amersham ECL Prime Western Blot Detection Reagent (GE Healthcare). 
 
2.9. Cell Viability Study 
100 μl DCs were seeded (2.5x105 cells/ml) with complete medium (α-MEM containing 
ribonucleosides, deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate 
supplemented with 20% FCS, 5 ng/ml murine GM-CSF and 1% antibiotic/antimycotic 
solution) in 96-well plates incubated at 37 °C, 5% CO2 for 4 h. 100 μl empty NPs dispersions 
in complete medium were added at concentration (0–2.5 mg/ml) (n=3), and 10% dimethyl 
sulfoxide (DMSO) as a positive control. The formulations were assayed for toxicity over 4 h 
incubation at 37 °C, followed by the addition of MTT (40 μl, 5 mg/ml) for 2 h. The complete 
medium was removed and replaced with DMSO (100 μl) in order to dissolve the formazan 
crystals. The absorbance was measured at 570 nm using a plate reader (Molecular Devices, 
SpectraMAX 190), and the percentage of viable cells was calculated as the absorbance ratio 
between NPs-treated and untreated control cells. 
 
2.10. Cellular Uptake of NPs by DCs 
The uptake of NPs by DCs in cell culture medium and PBS were visualized using the 
confocal laser scanning microscopy (CLSM) (Carl Zeiss LSM 710, UK). The DCs (2x105 
cells per well) were seeded onto an 8-well chambered #1 borosilicate coverglass system 
(Nunc Lab-Tek, Thermo Scientific, UK) and incubated at 37 ºC for 48 h. NPs at 
concentrations of 2.5 - 5 µg/ml were incubated for 1 h at 37 ºC with DCs. Following this, the 
supernatant was removed, washed three times with PBS and the DCs were fixed with 4% 
paraformaldehyde (Fisher Scientific, UK) for 10 min at room temperature. The DCs were 
then washed three times with PBS and 100 µl of 5 µg/ml wheat germ agglutinin antibody 
(WGA, Alexa Fluor® 488 Conjugate, Life Technologies, UK) was added and incubated at 37 
ºC for 15 min. The excess antibody was removed by washing three times with PBS followed 
by staining the nucleus of DCs with 100 µl of 20 µg/ml 4',6-diamidino-2-phenylindole, 
dilactate (DAPI, Sigma Aldrich, UK), and then incubated for 10 min at room temperature. 
Excess DAPI was removed by washing three times with PBS.  
 
2.11. In vitro Aerosolization Studies 
PspA4Pro adsorbed NPs/NCMPs were weighed into capsules (Hypromellose, HPMC, 
capsule, size 3, each corresponding to 12.5 mg spray-dried powder and equivalent to 5 mg 
of NPs) and placed in a Cyclohaler® (Teva Pharmaceutical Industries Ltd). A pump (Copley 
Scientific, Nottingham, UK) operated at a flow rate of 60 L/min for 4 s (corresponding to 4 
KPa pressure drop across the inhaler) drew samples through the next generation impactor 
(NGI, Copley Scientific, Nottingham, UK). Samples were collected from the NGI using 
distilled water and left on a roller-shaker for 48 h for the PspA4Pro to be released from the 
NCMPs and then centrifuged using an ultracentrifuge. The supernatant was analyzed using 
HPLC method. The percentage deposition (%) of protein was calculated as the percentage 
ratio of protein amount collected in each stage to that of total amount of protein collected in 
all stages. The fine particle fraction (FPF, %) was determined as the fraction of emitted dose 
deposited in the NGI with dae < 4.46 μm, the mass median aerodynamic diameter (MMAD, 
µm) was calculated from log-probability analysis, and the fine particle dose (FPD, µg) was 
expressed as the mass of drug deposited in the NGI with dae < 4.46 μm (n=3) in one 
actuation.  
 
2.12. Statistical Analysis 
One-way analysis of variance (ANOVA) with Tukey’s comparison using Minitab® 17 
Statistical Software was employed for comparing the formulations, with statistical significant 
differences determined as p<0.05. All values are expressed as mean ± standard deviation. 
 
3. Results 
3.1. PspA4Pro Adsorption and Quantification 
 The average adsorption of PspA4Pro onto NPs was 19.68±2.74 µg per mg of NPs. Table 
1 lists the particle size, PDI and zeta-potential of PGA-co-PDL NPs with and without 
PspA4Pro adsorption. The significant increase in particle size (p<0.05) of NPs accompanied 
with a change in the surface charge can be ascribed to the adsorption of PspA4Pro onto 
NPs. 
 
3.2. Characterization of Nanocomposite Microparticles  
 
3.2.1. Yield, Particle Size and Morphology 
  A reasonable yield of spray-dried NCMPs was obtained; with 55.55±6.64% for the 
PspA4Pro adsorbed NPs/NCMPs. The SEM pictures (Figure 1) of blank NPs/NCMPs 
revealed the shape to be irregular with a corrugated surface texture. The size of NCMPs 
calculated from SEM pictures was approximately 1.99±0.25 µm. 
 
3.2.2. In vitro Release Studies 
  The cumulative percentage of PspA4Pro released over time from NPs/NCMPs (Figure 
2), indicated an initial burst release of 40.59±4.94% was observed followed by continuous 
release of 89.81±2.95% up to 5 h, eventually reaching 94.30±2.90% over 48 h. 
 
3.2.3. In vitro Aerosolization Studies 
The deposition data obtained displayed a FPD of 60.02±8.56 µg (per capsule of 12.5 
mg), FPF of 74.31±1.32% and MMAD of 1.70±0.03 μm suggesting that the formulation was 
capable of delivering efficient PspA4Pro to the bronchial-alveolar region of the lungs. Figure 
3 shows the percentage stage-wise deposition of PspA4Pro in NGI. 
 
3.3. Investigation of PspA4Pro Structure 
The PspA4Pro released from the NPs/NCMPs was analyzed for primary and secondary 
structure using SDS-PAGE and CD, respectively. Figure 4 (a) indicates that the PspA4Pro 
released from NPs/NCMPs remained intact, based on the presence of a single band between 
43 and 66 KDa, and no other bands of either small or large MW were visible indicating no 
degradation or aggregation, respectively. 
The conformational changes of PspA4Pro released from the NPs/NCMPs and PspA4Pro 
supernatant after adsorption onto NPs and centrifugation were investigated by CD 
spectroscopy. Figure 4 (b and c) represents the CD spectra of standard PspA4Pro, 
PspA4Pro supernatant, and PspA4Pro released from the NPs/NCMPs. The spectra indicate 
two characteristic minima at 208 and 222 nm, known to be associated with α-helical 
structure. The data for the spectra presented in Table 2, for standard PspA4Pro, PspA4Pro 
supernatant and PspA4Pro released, indicated that the predominant structure of the protein 
was helical displaying 64.5, 64 and 51% helicity. Hence, the α-helical content of PspA4Pro 
released when compared to the standard, decreased by 13.5%. 
 
3.4. Antibody Recognition Test of PspA4Pro Integrity and Lactoferrin 
Binding 
 The antibody recognition of released PspA4Pro from NPs/NCMPs was determined using 
ELISA with a specific anti-PspA monoclonal antibody and represented as relative antibody 
recognition. The assay measures the ability of released PspA4Pro to bind and be recognized 
by an anti-PspA antibody. Figure 5 (a) shows that the PspA4Pro released from the NCMPs 
maintained its integrity with relative antibody recognition of 0.97±0.20 compared to 
PspA4Pro standard. To analyze the maintenance of important functional epitopes in the 
PspA4Pro released from NPs/NCMPs, the binding of PspA4Pro to lactoferrin was 
investigated. As shown in Figure 5 (b), PspA4Pro recovered from the NPs/NCMPs (lane 1) 
was able to bind to lactoferrin, indicating that the lactoferrin-binding site is intact in the 
sample. Lanes 2 and 3 show the binding of lactoferrin to control standard PspA4Pro. 
 
3.5. Cell Viability Study & Cellular Uptake of NPs by DCs 
The toxicity of non-loaded PGA-co-PDL NPs following 4 h incubation using a DC cell 
line, were assessed by the MTT assay. The NPs (Figure 6) showed increased cell death with 
an increase in NPs concentration. The NPs showed up to 90% cell viability at 19.53 µg/ml 
concentration that reduced to ~55% at 1.25 mg/ml concentration. The uptake of NR/NPs by 
DCs was observed using confocal microscopy. The cell wall of the DCs (stained with WGA 
Alexa Fluor® 488), the nucleus (stained with DAPI) and the NPs (containing Nile Red) were 
observed under the green, blue and red channel, respectively. Figures 7 shows the split view 
of DCs incubated with NR/NPs for 1 h in cell culture medium and PBS buffer, respectively. In 
addition, the orthogonal view NR/NPs uptake in cell culture medium and PBS buffer can be 
seen in Figure 8. 
 
4. Discussion 
Here, we utilized the optimum conditions from our previous study, of model protein 
adsorption onto polymeric particles (Kunda et al., 2015), for PspA4Pro adsorption onto PGA-
co-PDL NPs. We spray-dried PspA4Pro adsorbed NPs producing NCMPs to develop a 
pneumococcal protein vaccine against S. pneumoniae to be delivered via dry powder 
inhalation. Additionally, we investigated the antigen stability and integrity in the final 
formulation. 
Approximately 20 µg of PspA4Pro was adsorbed per mg of PGA-co-PDL NPs. The 
adsorption achieved with PspA4Pro was almost twice that of bovine serum albumin (BSA, 10 
µg per mg of NPs) as reported by Kunda et al (Kunda et al., 2015). This could be related to 
the MW of PspA4Pro (~43-50 KDa) being smaller than BSA (~66 KDa) thus providing more 
space on the NPs for PspA4Pro to adsorb. In addition, the elongated structure of PspA4Pro 
could enable the accommodation of more protein molecules on the surface of the NPs 
(Stolnik et al., 2001). 
PspA has both negative and positive ends; however, in distilled water (pH ~7) the protein 
carries a net negative charge as the pH is greater than the pI of PspA (4.82). The adsorption 
process was performed in distilled water, and at this pH, the protein was negatively charged 
and hydrophobic interactions and hydrogen bonding would be the dominant forces of 
adsorption onto the NPs, which had a negative zeta potential. Adsorption of PspA4Pro onto 
the surface of the NPs led to an increase in the hydrodynamic diameter as evident from the 
increase in particle size. In addition, the decrease in surface charge could be due to the 
protein molecules orientation adopted on the surface of the NPs exposing only a small part 
of the protein. Similar results have been reported by Koppolu et al. and Gordon et al. 
(Gordon et al., 2008; Koppolu and Zaharoff, 2013). 
The PspA4Pro adsorbed NPs were spray-dried into NCMPs using L-leu as a microcarrier, 
displaying a rough and wrinkled surface texture. This has been widely reported in the 
literature, together with benefits for dry powder aerosolization (Seville et al., 2007; Sou et al., 
2013; Tawfeek et al., 2011; Tawfeek et al., 2013). The FPF (~74%) and MMAD (~1.7 µm) 
obtained for the PspA4Pro adsorbed NPs/NCMPs suggest an excellent aerosolization 
performance similar to that observed for BSA adsorbed NPs/NCMPs (FPF: ~77 % and 
MMAD: 1.21 µm) (Kunda et al., 2015).  
The in vitro release data from PspA4Pro adsorbed NPs/NCMPs indicated a burst release 
of 40% with complete release (~94%) within 48 h. Though a high burst release was 
observed, this would not be a limiting factor for vaccination because any antigen released 
can still be taken up by DCs for processing and presentation, and that which is adsorbed 
onto NPs (intact) can also be taken up potentially giving an adjuvant effect as reported by 
Ghotbi et al., Cruz et al. and others (Carrillo-Conde et al., 2011; Cruz et al., 2012; Ghotbi et 
al., 2011). Further, it has been established that for NPs to act as an immune potentiator or 
adjuvant, the attachment of NPs and antigen may not be mandatory; hence, the particles 
without antigen adsorbed can be taken up by DCs enhancing the immune response (Zhao et 
al., 2014). Moreover, studies in the literature have reported the uptake of particles by DCs 
within 1-2 h of incubation (Cruz et al., 2012; Karagouni et al., 2013; Saleem et al., 2005). 
The structure of PspA4Pro released from NPs/NCMPs was investigated using SDS-PAGE 
(primary structure) and CD (secondary structure). The SDS-PAGE of PspA4Pro released 
from the formulations confirmed that the protein had not degraded based on the presence of 
a single band. This shows that the protein remained intact during the adsorption, spray-
drying process and desorption. In addition, the CD spectral data obtained for the released 
PspA4Pro confirmed the presence of α-helix and β-sheets. However, there is a decrease in 
the helical content observed (~13%). This effect could be due to the adsorption and 
desorption process or spray-drying. However, the antigenicity of released PspA4Pro showed 
the ability to effectively recognize and bind to the anti-PspA monoclonal antibody. 
Furthermore, the lactoferrin-binding site of PspA4Pro is functional after release from the 
NPs/NCMPs. This suggests that despite the reduction of α-helix structure the functional part 
of the antigen is still active. The results obtained with SDS-PAGE, CD antibody recognition 
and lactoferrin binding provides an indication that PspA delivered via NPs/NCMPs is stable 
and retains antigenicity for generating an immune response. 
PspA administered nasally (through a mucosal site) with an adjuvant into mice, a dose of 
only 100 ng was required to generate an immune response equivalent to that elicited by oral 
administration of 7.5 µg (Yamamoto et al., 1998). Considering that the NCMPs produced 
here are to be administered via inhalation i.e. through a mucosal site, the dose required 
would be ~ 100 ng of PspA for mice, requiring NCMPs concentrations lower than 20 µg/ml. 
However, the dose of PspA4Pro would be different for human immunization via the 
pulmonary route (yet to be determined). In addition, it has been shown the clinical dose 
required for pneumococcal polysaccharide vaccine administered via nebulized inhalation is 
estimated to be about 25 µg (Menzel et al., 2005; Meyer et al., 2006). Furthermore, 
intramuscular administration of rPspA achieved antibody responses at 25 µg (Nabors et al., 
2000). Although the mechanisms of immune response between polysaccharide and PspA 
are different, if we assume a similar dose is required for dry powder pulmonary delivery, then 
using PGA-co-PDL NPs/NCMPs we are able to deliver 60.02±8.56 ug of PspA (FPD per 
capsule of 12.5 mg). Hence, we can adjust the amount of spray-dried powder to 
approximately 5.21 mg to achieve the relevant 25 µg dose. 
It has now become evident that particulate antigens provide a Th1 type immune response 
(Couvreur and Vauthier, 2006; Gamvrellis et al., 2004; Joshi et al., 2013). In addition, the 
size, charge, shape and site of delivery all affect the extent of DCs uptake and thus the 
immune response generated (Joshi et al., 2013), with NPs < 500 nm showing higher uptake 
and activation of DCs and inducing stronger immune responses (Foged et al., 2005; Joshi et 
al., 2013; Koppolu and Zaharoff, 2013). Here, to substantiate our claims of effective uptake 
by DCs upon producing NPs of size ~ 300 nm, their uptake in JAWS II DC cell type was 
visualized using confocal microscopy. In cell culture media, NR fluorescence was detected 
when PGA-co-PDL NR/NPs were co-incubated with DCs for 1 h indicating the presence of 
NR/NPs within the DCs. However, Xu et al. have recently observed that NR, a lipophilic dye 
often used to stain intercellular lipid bodies, was released in the presence of cell culture 
medium and/or transferred directly to the cell membrane of contacting cells (Xu et al., 2009). 
It was also observed that the release of NR was significantly impeded in PBS. To investigate 
if the red fluorescence signals seen within the DCs is indeed the NR/NPs or the released 
NR, the uptake studies were repeated by co-incubating the NR/NPs with DCs in PBS 
medium. The presence of the red fluorescence was evident for PGA-co-PDL NR/NPs 
confirming their internalization by DCs thereby effectively endorsing the suitability of the size 
of NPs produced for vaccine delivery. 
 
5. Conclusion 
The results obtained above show that PspA4pro can effectively be adsorbed onto PGA-co-
PDL NPs (~20 µg of PspA4Pro per mg of NPs). The stability (primary and secondary 
structure) of the released PspA4Pro was maintained and relative antigenicity has been 
retained. Moreover, the functional part of the antigen was active in the formulation as 
determined by lactoferrin binding. In addition, the aerosol properties (FPF of 74.31±1.32% 
and MMAD of 1.70±0.03 μm) indicate deposition in the respirable airways i.e. the bronchial-
alveolar region of the lungs, ideal for antigen uptake by DCs. Moreover, PGA-co-PDL NPs 
when co-incubated with DCs showed internalization within 1 h. Further investigations would 
focus on determining the immunogenicity of the released PspA4Pro in vivo. 
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 Figure 1. SEM pictures of spraydried NPs/NCMPs. Scale bar (A) 20 µm and (B) 2 µm.  
 
Figure 2. In vitro release of pneumococcal surface protein A (PspA4Pro) from NPs/NCMPs in 
phosphate buffer saline, pH 7.4 (Mean±SD, n=3) 
 
Figure 3. The percentage deposition of pneumococcal surface protein A (PspA4Pro) stage-
wise in next generation impactor (NGI) (Mean±SD, n=3) 
 
Figure 4. (A) SDS-PAGE of Lane 1: MW standards, broad range (Bio-Rad Laboratories, 
Hercules CA, USA), Lane 2 & 3: pneumococcal surface protein A (PspA4Pro) standard, Lane 
4 & 5: Released PspA4Pro from NPs/NCMPs after 48 h. Circular Dichroism (CD) spectra of 
pneumococcal surface protein A (PspA4Pro) standard (black) from: (B) adsorbed PGA-co-
PDL NPs, supernatant (grey) and (C) PGA-co-PDL NPs/NCMPs, released (grey)   
 Figure 5. (A) Antibody recognition of pneumococcal surface protein A (PspA4Pro) upon 
release from NPs/NCMPs, (B) Lactoferrin binding of released PspA4Pro from NPs/NCMPs. 
Lane 1: PspA4Pro released from NCMPs, Lane 2 & 3: PspA4Pro standard at 100 ng and 250 
ng respectively  
 
Figure 6. Dendritic Cells (DCs) cell viability measured by MTT assay after 4 h exposure to 
PGA-co-PDL nanoparticles (NPs) (Mean±SD, n=3) 
 
Figure 7. Confocal microscopic images depicting a split view of dendritic cells (DCs) (40X 
lens) incubated in the absence and presence of Nile Red (NR)/nanoparticles (NPs) in (A) cell 
culture medium or (B) phosphate buffer saline (PBS) for 1 h (Scale bar – 20 µm) 
Figure 8. Confocal microscopic images depicting an orthogonal view of DCs (40X lens) 
incubated in the absence and presence of Nile Red (NR)/nanoparticles (NPs) in cell culture 
medium and phosphate buffer saline (PBS) for 1 h. 
 
Table 1. Particle size, PDI and zeta-potential of PGA-co-PDL nanoparticles (NPs) with and 
without pneumococcal surface protein A (PspA4Pro) adsorption (Mean±SD, n=3) 
 Without adsorption With adsorption 
Particle Size (nm) 203.90±2.55a)* 322.83±04.25 b)* 
PDI 0.205±0.007 0.402±0.018 
Zeta-potential (mV) -24.56±0.50 -13.23±0.11 
a) NPs characterised after centrifugation, b) NPs characterised after centrifugation, * p < 0.05, ANOVA/Tukey’s 
 
 
 
 Table 2. The percentages of secondary structures of standard, supernatant and released 
pneumococcal surface protein A (PspA4Pro) samples 
 
 
 
 
 
Fig .1 
 
Fig .2 
Sample Helix Strand Turns Unordered 
Standard PspA4Pro 64.50±0.02 06.00±0.00 07.50±0.00 22.00±0.01 
PspA4Pro Supernatant 64.00±0.02 07.00±0.01 08.00±0.01 20.50±0.01 
PspA4Pro Released 51.00±0.03 21.00±0.01 07.50±0.01 20.00±0.03 
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